Regeneron drug tames eczema in study

By Natalie Huet and Ransdell Pierson PARIS/NEW YORK (Reuters) – An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly controlled by standard drugs, the companies said on Wednesday. Dupilumab was named "clinical advance of the year" in 2013 by industry publication Scrip Intelligence, and some analysts expect it to capture annual sales up to $2 billion if approved.